In what form is Asmanex (Mometasone) administered for patients aged 12 and older?

Mometasone, marketed under the name Asmanex, is delivered as a dry powder inhaler (DPI) and is specifically indicated for asthma management in patients aged 12 and older. The formulation and dosing frequency are critical in providing effective asthma control while minimizing potential side effects.

In this case, the correct choice indicates that Mometasone is administered twice daily using a metered-dose inhaler (MDI). This configuration allows for effective distribution of the medication to the lungs, where it can exert its anti-inflammatory effects targeted at asthma control. The twice-daily regimen is designed to maintain stable therapeutic levels of the medication to manage asthma symptoms effectively throughout the day.

Other options, while they also indicate forms of inhalation therapy, do not accurately reflect the approved and effective administration schedule for Mometasone in this age group according to clinical guidelines.